VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in metastatic colorectal carcinoma (CRC) treatment, but responses are unpredictable. Vascular endothelial growth factor is alternatively spliced to form proangiogenic VEGF(165) and antiangiogenic VEGF(165)b. Using iso...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Varey, A, Rennel, E, Qiu, Y, Bevan, H, Perrin, R, Raffy, S, Dixon, A, Paraskeva, C, Zaccheo, O, Hassan, A, Harper, S, Bates, DO
פורמט: Journal article
שפה:English
יצא לאור: 2008

פריטים דומים

פריטים דומים